Lancet Oncology Publishes! Efficacy and Safety of DS-8201 in Treating HER2-Positive Lung Cancer
Source: Professor Zhang Bo The activation mechanisms of the HER-2 gene include amplification, mutation, insertion, and protein overexpression. Although HER-2 is considered a driver gene in lung cancer, no targeted therapeutic drugs have been approved. Recently, Lancet Oncology published efficacy and safety data for the ADC drug DS-8201 targeting HER2 in patients with advanced NSCLC … Read more
